Bill & Melinda Gates Medical Research Institute    [to 9 Jun 2018]
   The Bill & Melinda Gates Medical Research Institute is a non-profit research organization dedicated to combating diseases that impact the world’s poorest. We strive to combat inequities in health by accelerating progress in translational science to ensure life-saving products are available and accessible to everyone. We consider ourselves pioneers dedicated to uncovering radical solutions that will close the gap between cutting-edge scientific innovation and its application to challenges in global health.

Forbes  Jun 7, 2018
Bill And Melinda Gates Start A Nonprofit Biotech In Boston
Matthew Herper,
The Bill & Melinda Gates Medical Research Institute, which is holding an event today to show off its plans, will aim to develop new medicines and vaccines for malaria, tuberculosis, and diarrhea, which together account for 2.6 million deaths a year globally, many of them in children.

EDCTP    [to 9 Jun 2018]
The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials
8 June 2018
European Commission presents next research & innovation framework ‘Horizon Europe’
The European Commission (EC)published its proposal for Horizon Europe, a €100 billion research and innovation programme, on 7 June 2018. The proposal is part of the next European Union long-term budget. Horizon Europe 2021 – 2027 will succeed Horizon 2020…

6 June 2018
Kick-off for trials of preventive vaccine for dermal leishmaniasis
The PREV-PKDL consortium prepares to start clinical trials of a candidate vaccine to prevent chronic dermal leishmaniasis in patients treated for visceral leishmaniasis. The kick-off meeting will take place in York (UK) on 6-7 June 2018.
The promising vaccine has been developed by Prof. Paul Kaye and his team at the University of York, United Kingdom. EDCTP invested EUR 8 million in the project (2018-2023) to prevent post kala azar dermal leishmaniasis (PKDL). The project is coordinated by Dr Odile Leroy, Executive Director of the European Vaccine Initiative (Germany).
Two phase II clinical trials will be conducted in Sudan to evaluate the safety and efficacy of the vaccine in patients diagnosed with and treated for visceral leishmaniasis. In parallel, the project partners also plan to conduct research studies in Sudan, Ethiopia, Kenya and Uganda to better understand the pathogenesis of the disease and the underlying immune mechanisms.

European Medicines Agency  [to 9 Jun 2018]
Highlights of 100th Management Board meeting: June 2018
Positive assessment of 2017 operations – Seat Agreement with the Netherlands signed
Gavi [to 9 Jun 2018]
07 June 2018
Gavi Board approves funding for inactivated poliovirus vaccine until 2020
Flexible support to Nigeria and post-transition countries also approved.
Geneva, 7 June 2018 – The Gavi Board today approved Gavi core funding for inactivated poliovirus vaccine (IPV) for 2019 and 2020 to contribute to achieving and safeguarding the eradication of polio.
“Polio will remain a threat until every child is protected against this crippling disease,” said Dr Ngozi Okonjo-Iweala, Gavi Board Chair. “That is why the vaccination of every child is the corner stone of the polio eradication effort. Introducing IPV to all countries to interrupt polio transmission and maintain zero cases represents an unprecedented push, and Gavi is proud to be part of it.”…

Gavi Board appoints Bill Roedy as Vice Chair
Former MTVNI CEO and HIV/AIDS advocate to help further protect millions of children from vaccine-preventable diseases
Geneva, 7 June 2018 – Bill Roedy, Global Health Ambassador and Former Chairman and Chief Executive Officer of MTV networks International (MTVNI), was today appointed by the Gavi Board as its new Vice Chair.
Mr Roedy joined Gavi in 2010 as its first envoy. He was appointed to the Board in 2015 and has been acting Vice Chair since April 2018.
“It is an honour to be appointed Vice Chair of the Gavi Board. At this level, I have never seen a leaner and more accountable, sustainable, efficient operation in all of global health, and in fact all of business,” said Mr Roedy. “Universal access to life-saving vaccines is the bedrock of a healthy society and a strong economy, and I look forward to supporting the Board Chair at this critical time for the Vaccine Alliance.”…
Mr Roedy replaces Gunilla Carlsson, former Swedish Minister for International Development Cooperation, who stepped down from the position earlier this year following her appointment as Deputy Executive Director, Management and Governance, UNAIDS, and Assistant Secretary General of the United Nations. As Vice Chair of the Board, Mr Roedy will also become chair of the Gavi Governance Committee.

GHIT Fund   [to 9 Jun 2018]
GHIT was set up in 2012 with the aim of developing new tools to tackle infectious diseases that devastate the world’s poorest people. Other funders include six Japanese pharmaceutical
June 7, 2018
GHIT Fund Names Hiroki Nakatani as Board Chair
TOKYO, JAPAN (June 7, 2018)—The Global Health Innovative Technology Fund (GHIT) today announced its appointment of Hiroki Nakatani, MD, PhD, MHPEd, former World Health Organization (WHO) assistant director-general, to the fund’s board of directors and named him its board chair. Nakatani succeeds founding GHIT Board Chair Kiyoshi Kurokawa, who played an instrumental role in the fund’s growth and achievements in its first five years of operation.
“Dr. Nakatani is a pioneer in global health and neglected tropical diseases, with an impeccable science and policy implementation track record. His unparalleled leadership in Japan and internationally in linking health innovation to effective policy and delivery will be critical as GHIT continues to evolve and as its first products hit the market,” said BT Slingsby, CEO and executive director of the GHIT Fund. “Dr. Nakatani joins the board at a very exciting time as we’ve also just launched our second five-year phase. And we are grateful to Dr. Kurokawa for his invaluable contributions.”
Nakatani served as WHO assistant director-general from 2007 to 2015, where he led the largest technical cluster comprising HIV/AIDS, tuberculosis, malaria and neglected tropical diseases. During his tenure, the morbidity and mortality of these diseases showed trends of decline, with some tropical diseases moving toward suppression and even eradication in the case of dracunculiasis (guinea worm disease)…

IVAC  [to 9 Jun 2018]
June 2018
Commentary: How can Nigeria achieve sustainable immunization financing in the next decade? Government, business, and health leaders discuss the way forward
a panel discussion on options open to the federal government to sustainably finance the routine immunization program ensued. The panel was moderated by Dr. Kate O’Brien, Executive Director of the International Vaccine Access Center (IVAC) at the Johns Hopkins Bloomberg School of Public Health.

NIH  [to 9 Jun 2018]
June 4, 2018
New approach to immunotherapy leads to complete response in breast cancer patient unresponsive to other treatments
— New approach is a modified form of adoptive cell transfer.

HIV vaccine elicits antibodies in animals that neutralize dozens of HIV strains
June 4, 2018 — NIH study results represent major advance for structure-based HIV vaccine design.

NIH releases strategic plan for data science
June 4, 2018 — The plan provides a roadmap for modernizing the NIH-funded biomedical data science ecosystem.
[See Milestones above for more detail]

UNAIDS [to 9 Jun 2018]
Feature story
Stepping up sexual and reproductive health services in Egypt
04 June 2018
In response to a call by women living with HIV in Egypt for an increase in the availability of quality sexual and reproductive health services delivered free from stigma and discrimination, UNAIDS mobilized partners and engaged with Egypt’s national AIDS programme.
The result was a pilot project that ran from 2016 to 2018 in which almost 300 women across the country were provided with family planning, antenatal care, support during delivery, postpartum care and guidance on the prevention of mother-to-child transmission of HIV.
On 30 May, national stakeholders, including representatives of the Ministries of Foreign Affairs and Health and Population, civil society, academia and people living with and affected by HIV, gathered to highlight the key achievements, experiences and lessons learned from the pilot…
Wellcome Trust  [to 9 Jun 2018]
News / Published: 4 June 2018
Update on Public Health and Tropical Medicine Fellowships
Wellcome’s fellowships for early to intermediate career researchers from low- or middle-income countries (LMICs) are being relaunched.
The schemes are being renamed as the International Master’s, Training and Intermediate Fellowships.
We’ve also updated the scope of the schemes to align with our science remit and strategy.
The International Master’s Fellowship will now have a fixed budget limit of £120,000, including salary, stipend, fees and research costs.
These changes follow a recent review and our aim is to attract a broader group of scientists with more diverse research backgrounds.
The Wistar Institute   [to 9 Jun 2018]
Press Release  Jun. 7, 2018
The Wistar Institute Partners with Nation’s Top Cancer Centers to Endorse Goal of Eliminating HPV-related Cancers in the United States
Joint statement empowers parents, young adults and physicians to act to increase vaccination rates and screenings in effort to eliminate HPV-related cancers, starting with cervical cancer.
{see Milestones above for more detail]

Press Release  Jun. 4, 2018
The Wistar Institute and Harbour BioMed Join Forces to Advance Novel Antibody Therapies for Cancer and Infectious Diseases
Collaboration combines Wistar’s cancer biology, immunology expertise with Harbour’s proprietary H2L2 transgenic mouse platform for generating fully human monoclonal antibodies.